Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea

Nutrition and Metabolism

Volumn 4, Issue , 2007, Pages

  Frostegård, Johan ^a   Tao, WenJing ^a   Georgiades, Anastasia ^b   Råstam, Lennart ^c   Lindblad, Ulf ^c   Lindeberg, Staffan ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN M ANTIBODY; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MYRISTIC ACID; PHOSPHORYLCHOLINE; SATURATED FATTY ACID;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART PROTECTION; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; LIFESTYLE; MALE; PAPUA NEW GUINEA; PROTEIN BLOOD LEVEL; RISK FACTOR; SMOKING; SWEDEN; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

EID: 34247228691     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-4-7     Document Type: Article

References (45)

1. Age relations of cardiovascular risk factors in a traditional Melanesian society: the Kitava Study. S Lindeberg E Berntorp P Nilsson-Ehle A Terent B Vessby, Am J Clin Nutr 1997 66 845 852 9322559
2. Low serum insulin in traditional Pacific Islanders - the Kitava Study. S Lindeberg M Eliasson B Lindahl B Ahren, Metabolism 1999 48 1216 1219 10.1016/S0026-0495(99)90258-5 10535381
3. Large differences in serum leptin levels between nonwesternized and westernized populations: the Kitava study. S Lindeberg S Soderberg B Ahren T Olsson, J Intern Med 2001 249 553 558 10.1046/j.1365-2796.2001.00845.x 11422662
4. Innate and adaptive immunity in the pathogenesis of atherosclerosis. GK Hansson P Libby U Schonbeck ZQ Yan, Circ Res 2002 91 281 291 10.1161/01.RES.0000029784.15893.10 12193460
5. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. J Frostegard AK Ulfgren P Nyberg U Hedin J Swedenborg U Andersson GK Hansson, Atherosclerosis 1999 145 33 43 10.1016/S0021-9150(99)00011-8 10428293
6. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. J Frostegard J Nilsson A Haegerstrand A Hamsten H Wigzell M Gidlund, Proc Natl Acad Sci U S A 1990 87 904 908 2300583 10.1073/pnas.87.3.904
7. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. JA Berliner MC Territo A Sevanian S Ramin JA Kim B Bamshad M Esterson AM Fogelman, J Clin Invest 1990 85 1260 1266 2318980
8. Induction of T-cell activation by oxidized low density lipoprotein. J Frostegard R Wu R Giscombe G Holm AK Lefvert J Nilsson, Arterioscler Thromb 1992 12 461 467 1558837
9. Oxidised LDL modulates immune-activation by an IL-12 dependent mechanism. GZ Fei YH Huang J Swedenborg J Frostegard, Atherosclerosis 2003 169 77 85 10.1016/S0021-9150(03)00146-1 12860253
10. Autoimmunity, oxidized LDL and cardiovascular disease. J Frostegard, Autoimmun Rev 2002 1 233 237 10.1016/S1568-9972(02)00059-9 12849001
11. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Y Shoenfeld R Wu LD Dearing E Matsuura, Circulation 2004 110 2552 2558 10.1161/01.CIR.0000143225.07377.EA 15505108
12. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. JT Salonen S Ylä-Herttuala R Yamamoto S Butler H Korpela R Salonen K Nyyssönen W Palinski JL Witztum, Lancet 1992 339 883 887 10.1016/0140-6736(92)90926-T 1348295
13. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. MF Lopes-Virella G Virella TJ Orchard S Koskinen RW Evans DJ Becker KY Forrest, Clin Immunol 1999 90 165 172 10.1006/clim.1998.4631 10080827
14. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. R Wu U de Faire C Lemne JL Witztum J Frostegard, Hypertension 1999 33 53 59 9931081
15. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). J Hulthe O Wiklund E Hurt-Camejo G Bondjers, Arterioscler Thromb Vasc Biol 2001 21 269 274 11156864
16. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. J Karvonen M Paivansalo YA Kesaniemi S Horkko, Circulation 2003 108 2107 2112 10.1161/01.CIR.0000092891.55157.A7 14530200
17. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. J Frostegard YH Huang J Ronnelid L Schafer-Elinder, Arterioscler Thromb Vasc Biol 1997 17 963 968 9157962
18. Oxidatively modified LDL contains phospholipids with platelet- activating factor-like activity and stimulates the growth of smooth muscle cells. JM Heery M Kozak DM Stafforini DA Jones GA Zimmerman TM McIntyre SM Prescott, J Clin Invest 1995 96 2322 2330 7593619
19. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis : in vitro and In vivo inhibition by WEB 2086. G Subbanagounder N Leitinger PT Shih KF Faull JA Berliner, Circ Res 1999 85 311 318 10455059
20. Phosphorylcholine: friend or foe of the immune system? W Harnett MM Harnett, Immunol Today 1999 20 125 129 10.1016/S0167-5699(98)01419-4 10203703
21. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. J Su A Georgiades R Wu T Thulin U de Faire J Frostegard, Atherosclerosis 2006 188 1 160 166 10.1016/j.atherosclerosis.2005.10.017 16307748
22. Apparent absence of stroke and ischaemic heart disease in a traditional Melanesian island: a clinical study in Kitava. S Lindeberg B Lundh, J Intern Med 1993 233 269 275 8450295
23. Differences in treatment and metabolic abnormalities between normo- and hypertensive patients with type 2 diabetes: the Skaraborg Hypertension and Diabetes Project. CJ Ostgren U Lindblad E Bog-Hansen J Ranstam A Melander L Rastam, Diabetes Obes Metab 1999 1 105 112 10.1046/j.1463-1326.1999.00018.x 11220508
24. Cardiovascular risk factors in a Melanesian population apparently free from stroke and ischaemic heart disease: the Kitava study. S Lindeberg P Nilsson-Ehle A Terent B Vessby B Schersten, J Intern Med 1994 236 331 340 8077891
25. Serum uric acid in traditional Pacific Islanders and in Swedes. S Lindeberg L Cordain L Rastam B Ahren, J Intern Med 2004 255 373 378 10.1046/j.1365-2796.2003.01272.x 14871461
26. Epidemiological perspective of body position and arm level in blood pressure measurement. A Terent E Breig-Asberg, Blood Press 1994 3 156 163 8069403
27. Fatty acid composition of platelets and of plasma lipid esters in relation to platelet function in patients with ischaemic heart disease. M Boberg B Vessby LB Croon, Atherosclerosis 1985 58 49 63 10.1016/0021-9150(85)90055-3 2936356
28. Oxidized LDL induces enhanced antibody formation and MHC class II-dependent IFN-gamma production in lymphocytes from healthy individuals. YH Huang J Ronnelid J Frostegard, Arterioscler Thromb Vasc Biol 1995 15 1577 1583 7583530
29. Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. YH Huang L Schafer-Elinder R Wu HE Claesson J Frostegard, Clin Exp Immunol 1999 116 326 331 10.1046/j.1365-2249.1999.00871.x 10337026
30. Phosphocholine as a pattern recognition ligand for CD36. A Boullier P Friedman R Harkewicz K Hartvigsen SR Green F Almazan EA Dennis D Steinberg JL Witztum O Quehenberger, J Lipid Res 2005 46 969 976 10.1194/jlr.M400496-JLR200 15722561
31. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. MK Chang C Bergmark A Laurila S Horkko KH Han P Friedman EA Dennis JL Witztum, Proc Natl Acad Sci U S A 1999 96 6353 6358 10339591 10.1073/pnas.96.11.6353
32. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. DE Briles C Forman S Hudak JL Claflin, J Exp Med 1982 156 1177 1185 10.1084/jem.156.4.1177 7153709
33. Innate-like B cells. JF Kearney, Springer Semin Immunopathol 2005 26 377 383 10.1007/s00281-004-0184-0 15645296
34. Innate and acquired immunity in atherogenesis. CJ Binder MK Chang PX Shaw YI Miller K Hartvigsen A Dewan JL Witztum, Nat Med 2002 8 1218 1226 10.1038/nm1102-1218 12411948
35. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. W Palinski E Miller JL Witztum, Proc Natl Acad Sci U S A 1995 92 821 825 7846059 10.1073/pnas.92.3.821
36. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. S Freigang S Horkko E Miller JL Witztum W Palinski, Arterioscler Thromb Vasc Biol 1998 18 1972 1982 9848892
37. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. CJ Binder S Horkko A Dewan MK Chang EP Kieu CS Goodyear PX Shaw W Palinski JL Witztum GJ Silverman, Nat Med 2003 9 736 743 10.1038/nm876 12740573
38. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. JR Faria-Neto KY Chyu X Li PC Dimayuga C Ferreira J Yano B Cercek PK Shah, Atherosclerosis 2006 189 1 83 90 10.1016/j. atherosclerosis.2005.11.033 16386745
39. Rupture of the atherosclerotic plaque: does a good animal model exist? P Cullen R Baetta S Bellosta F Bernini G Chinetti A Cignarella A Von Eckardstein A Exley M Goddard M Hofker E Hurt-Camejo E Kanters P Kovanen S Lorkowski W McPheat M Pentikainen J Rauterberg A Ritchie B Staels B Weitkamp M De Winther, Arterioscler Thromb Vasc Biol 2003 23 535 542 10.1161/01.ATV.0000060200.73623.F8 12615660
40. High anti-phosphorylcholine antibody levels and mortality associated with pneumonia. G Nordenstam B Andersson D Briles JW Brooks Jr. A Oden A Svanborg CS Eden, Scand J Infect Dis 1990 22 187 195 2356441
41. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. VN Bochkov A Kadl J Huber F Gruber BR Binder N Leitinger, Nature 2002 419 77 81 10.1038/nature01023 12214235
42. Signalling mechanisms underlying subversion of the immune response by the filarial nematode secreted product ES-62. HS Goodridge G Stepek W Harnett MM Harnett, Immunology 2005 115 296 304 15946247 10.1111/j.1365-2567.2005.02167.x
43. Clinical documentation of twenty cases of acute myocardial infarction in Papua New Guineans. IH Kevau, P N G Med J 1990 33 275 280 2099047
44. Diabetes, the emerging problem in Papua New Guinea. MS Patel, P N G Med J 1984 27 1 3 6595897
45. Stroke in Papua New Guinea. S Lindeberg, Lancet Neurol 2003 2 273; discussion 273 12849179